API firm Unimark Remedies warned by US FDA about Indian plants

By Gareth Macdonald

- Last updated on GMT


Related tags Pharmaceutical drug

The US FDA has warned API manufacturer Unimark Remedies about unsanitary conditions at its facility in Vapi and Bavla in India.

The US regulator detailed its concerns about Unimark in a warning letter​ this week, explaining that inspectors who visited the facilities in May and August 2015 observed a number of deviations from current good manufacturing practice (cGMP) standards.

At the Vapi site, the agency found evidence Unimark had failed to investigate out-of-spec test results and had changed active pharmaceutical ingredient (API) production process without assessing the impact of doing so.

Meanwhile, inspectors who visited the Bavla site saw “dirt and birds in the manufacturing area” and “a lizard in the controlled-processing area​” according to the letter.

They also criticized Unimark for failing to document out-of-spec results, ensure that testing procedures were scientifically sound and poor staff training at the Bavla facility.

The warning letter is the second the US Food and Drug Administration (FDA) has sent to Unimark in 12 months.

Last September​, the agency criticized operations at the Bavla site, citing a failure to document production and analytical testing activities.

Jordanian drug manufacturer Hikma​ recently sold a minority stake in Unimark that it acquired in 2011 for $33m (€29.2m). The sale was a condition of Hikma's acquisition of Roxane Laboratories​.

A Hikma spokeswoman told us "we don’t disclose information regarding our suppliers​" when we asked in the firm bought APIs from Unimark.

Related news

Show more

Related products

show more

Increasing the Bioavailability of Oncology Drugs

Increasing the Bioavailability of Oncology Drugs

Content provided by Lonza Small Molecules | 13-Nov-2023 | White Paper

Oral tyrosine kinase inhibitors (TKIs) are a class of cancer drugs that can be highly susceptible to issues with solubility in the gastrointestinal tract

Efficient Freezing & Storage of Biopharmaceuticals

Efficient Freezing & Storage of Biopharmaceuticals

Content provided by Single Use Support | 06-Nov-2023 | White Paper

Various options exist for freezing biopharmaceutical bulk material, but selecting the most effective and efficient approach for each cold chain can be...

Manufacturing Drugs with Highly Potent APIs

Manufacturing Drugs with Highly Potent APIs

Content provided by Altasciences | 28-Sep-2023 | White Paper

In this issue of The Altascientist, we examine the critical considerations for the safe and compliant manufacture of drugs with highly potent APIs (HPAPIs),...

Follow us